---
title: Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular
  lymphoma after ≥2 prior therapies
date: '2024-10-24'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39447094/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20241024201600&v=2.18.0.post9+e462414
source: Blood
description: Mosunetuzumab, a CD20xCD3 T-cell engaging bispecific antibody, redirects
  T cells to eliminate malignant B cells. We present updated efficacy and safety data
  of a pivotal phase 1/2 study after a median follow-up of 37.4 months in 90 patients
  with relapsed/refractory (R/R) follicular lymphoma (FL) and ≥2 prior lines of therapy
  treated with fixed-duration mosunetuzumab. Investigator-assessed complete response
  (CR) rate and objective response rate (ORR) were 60.0% (95% confidence interval
  ...
disable_comments: true
---
Mosunetuzumab, a CD20xCD3 T-cell engaging bispecific antibody, redirects T cells to eliminate malignant B cells. We present updated efficacy and safety data of a pivotal phase 1/2 study after a median follow-up of 37.4 months in 90 patients with relapsed/refractory (R/R) follicular lymphoma (FL) and ≥2 prior lines of therapy treated with fixed-duration mosunetuzumab. Investigator-assessed complete response (CR) rate and objective response rate (ORR) were 60.0% (95% confidence interval ...